Skip to main content
Print Save

Admelog FDA Approval History

FDA Approved: Yes (First approved December 11, 2017)
Brand name: Admelog
Generic name: insulin lispro
Dosage form: Injection
Company: Sanofi
Treatment for: Diabetes, Type 1, Diabetes, Type 2

Admelog (insulin lispro) is a follow-on rapid-acting human insulin analog (referenced to Humalog) for the treatment of patients with type 1 and type 2 diabetes.

Development timeline for Admelog

DateArticle
Dec 11, 2017Approval FDA Approves Admelog (insulin lispro) Rapid-Acting "Follow-On" Insulin Product to Treat Diabetes
Sep  1, 2017Sanofi Receives Tentative FDA Approval of Admelog (insulin lispro injection) 100 units/mL

See also

Admelog (insulin lispro) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer